Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: -others

Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study

Claire Fournier, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation

Published 7 November 2018
Categorized as -others, 2018, Publication, TG1050

Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy

Karola Rittner, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation

Published 7 November 2018
Categorized as -others, 2018, Publication

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity

Alan Anthoney, et al. ASCO 2018, June 2018 – Abstract available on the ASCO website Download the poster here Poster Presentation

Published 17 May 2018
Categorized as -others, 2018, Pexa-Vec, Publication

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis

Stephane Leung-Theung-Long, et al. PLOS One, May 2018 – Download the article Publication

Published 2 May 2018
Categorized as -others, 2018, Publication, TB Program

Pseudocowpox: A next generation viral vector for cancer immunotherapy

Karolina Rittner, et al. AACR 2018, April 2018 – Abstract available on the AACR 2018 website Download the poster here Poster Presentation

Published 18 April 2018
Categorized as -others, 2018, Publication

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation

Published 17 April 2018
Categorized as -others, 2018, Publication, TG6002

TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B

Martin F. Sprinzl, et al. AASLD & Hepatology, October 2017 Download the poster here Poster Presentation

Published 23 October 2017
Categorized as -others, 2018, Publication, TG1050

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Caroline Tosch, et al. Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article Publication

Published 12 October 2017
Categorized as -others, 2017, Publication, TG4010

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy-Ziller, et al. Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article Publication

Published 12 October 2017
Categorized as -others, 2017, Publication, TG4010

A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation

Published 7 September 2017
Categorized as -others, 2017, Pexa-Vec, Publication Tagged Oncolytic virus, Poster presentation

Posts pagination

Newer posts Page 1 … Page 6 … Page 10 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu